ArticleScience advances2022
Preneoplastic somatic mutations including
Open access · goldAbstract read
In one paragraph
Article in Science advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
6.0field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 39 citations in OpenAlex.
- Clonotypic characterization defines B-cell drivers of clonal expansion and intratumor heterogeneity in IgM monoclonal gammopathies.HemaSphere · 2026Article
- WNK2 oncogenicity revealed by the discovery and functional characterization of novel gene isoforms in MYD88 mutated Waldenström's Macroglobulinemia.Blood cancer journal · 2026Article
- Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas.Molecular cancer · 2026Article
- Review
- Review
- Multiplexed imaging mass cytometry elicits p-S6 as a therapeutic and prognostic factor in diffuse large B-cell lymphoma.Blood advances · 2025Article
- A rare case of splenic marginal zone lymphoma with MYD88 mutation transformed into diffuse large B-cell lymphoma: case report and literature review.Annals of hematology · 2025Review
- Genomic and immune profiling of prognostic risk groups in IgM gammopathy reveals novel biomarkers beyondFrontiers in immunology · 2025Article
- Prognostic risk and survival of asymptomatic IgM monoclonal gammopathy: Results from a Spanish Multicenter Registry.HemaSphere · 2024Article
- B cell receptor signaling and associated pathways in the pathogenesis of chronic lymphocytic leukemia.Frontiers in oncology · 2024Review
- Genetics and epidemiology of mutational barcode-defined clonal hematopoiesis.Nature genetics · 2023Article
- Current approach to Waldenström macroglobulinemia.Blood reviews · 2023Review
- Clonal architecture and evolutionary history of Waldenström's macroglobulinemia at the single-cell level.Disease models & mechanisms · 2023Article
- Dysfunctions of innate and adaptive immune tumor microenvironment in Waldenström macroglobulinemia.International journal of cancer · 2023Article
- Transcriptome Analysis of Diffuse Large B-Cell Lymphoma Cells Inducibly Expressing MyD88 L265P Mutation Identifies Upregulated CD44, LGALS3, NFKBIZ, and BATF as Downstream Targets of Oncogenic NF-κB Signaling.International journal of molecular sciences · 2023Article
- Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management.American journal of hematology · 2023Article
- An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas.Cancer discovery · 2023Article
- Prognostic impact of MYD88 and CXCR4 mutations assessed by droplet digital polymerase chain reaction in IgM monoclonal gammopathy of undetermined significance and smouldering Waldenström macroglobulinaemia.British journal of haematology · 2023Article
- Mouse models of diffuse large B cell lymphoma.Frontiers in immunology · 2023Review
- Single-cell profiles reveal tumor cell heterogeneity and immunosuppressive microenvironment in Waldenström macroglobulinemia.Journal of translational medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
38 authors at 11 institutions in 5 countries.
Sara RodriguezClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.ORCID 0000-0001-6509-0447
Jon CelayClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.ORCID 0000-0002-2017-4206
Ibai GoicoecheaClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.ORCID 0000-0002-5329-2225
Cristina JimenezHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC, Salamanca, Spain.ORCID 0000-0002-5543-5154
Cirino BottaDepartment of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties, University of Palermo, Palermo, Italy.ORCID 0000-0002-1522-4504
Maria-José Garcia-BarchinoClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
Juan-Jose GarcesClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.ORCID 0000-0001-9235-4671
Marta LarrayozClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.ORCID 0000-0001-6097-8244
Susana SantosCentro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.ORCID 0000-0001-5947-6845
Diego AlignaniClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.ORCID 0000-0003-0241-1375
Amaia Vilas-ZornozaClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
Cristina PerezClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.ORCID 0000-0003-3586-2666
Sonia GarateClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
Sarai SarvideClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
Aitziber LopezClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
Hans-Christian ReinhardtDepartment of Hematology and Stem Cell Transplantation, West German Cancer Center, DKTK Partner Site Essen, Center for Molecular Biotechnology, University Hospital Essen, Hufelandstr. 55, 45147, Essen, Germany.
Yolanda R CarrascoDepartment of Immunology and Oncology, Centro Nacional de Biotecnología (CNB)-CSIC, Madrid, Spain.ORCID 0000-0003-2148-1926
Isidro Sanchez-GarciaExperimental Therapeutics and Translational Oncology Program, Instituto de Biología Molecular y Celular del Cáncer, CSIC/Universidad de Salamanca and Institute of Biomedical Research of Salamanca (IBSAL), Salamanca, Spain.ORCID 0000-0001-6989-9905
Maria-Jose LarrayozClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.
Maria-Jose CalasanzClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.ORCID 0000-0002-0374-3008
Carlos PanizoClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.ORCID 0000-0002-3945-585X
Felipe ProsperClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.ORCID 0000-0001-6115-8790
Jose-Maria Lamo-EspinosaClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.ORCID 0000-0002-9696-2620
Marina MottaDepartment of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.
Alessandra TucciDepartment of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy.ORCID 0000-0003-3052-7463
Antonio SaccoClinical Research Development and Phase I Unit, ASST Spedali Civili di Brescia, Brescia, Italy.ORCID 0000-0003-2945-9416
Massimo GentileDepartment of Oncohematology, "Annunziata" Hospital, Cosenza, Italy.
Sara DuarteCentro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.ORCID 0000-0002-7641-175X
Helena VitoriaHospital de S. Teotónio, Viseu, Portugal.
Catarina GeraldesCentro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.
Artur PaivaCentro Hospitalar e Universitario de Coimbra, Coimbra, Portugal.ORCID 0000-0002-6562-5859
Noemi PuigHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC, Salamanca, Spain.ORCID 0000-0001-7535-3861
Ramon Garcia-SanzHospital Universitario de Salamanca, Instituto de Investigacion Biomedica de Salamanca (IBSAL), Centro de Investigación del Cancer (IBMCC-USAL, CSIC), CIBER-ONC, Salamanca, Spain.ORCID 0000-0003-4120-2787
Aldo M RoccaroClinical Research Development and Phase I Unit, ASST Spedali Civili di Brescia, Brescia, Italy.ORCID 0000-0002-1872-5128
Gema FuerteMission Bio, San Francisco, CA, USA.ORCID 0000-0003-3233-0218
Jesus F San MiguelClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.ORCID 0000-0002-9183-4857
Jose-Angel Martinez-ClimentClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.ORCID 0000-0002-7938-3950
Bruno PaivaClinica Universidad de Navarra, Centro de Investigacion Medica Aplicada (CIMA), Instituto de Investigacion Sanitaria de Navarra (IDISNA), CIBER-ONC, Pamplona, Spain.ORCID 0000-0003-1977-3815
Navarre Institute of Health Research · ESAzienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITHospitais da Universidade de Coimbra · PTInstituto de Investigación Biomédica de Salamanca · ESCentro Nacional de Biotecnología · ESEssen University Hospital · DEHospital São Teotónio · PTMission Bio (United States) · USOspedale Annunziata di Cosenza · ITUniversidad de Salamanca · ESUniversity of Palermo · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
Normal cell counterparts of solid and myeloid tumors accumulate mutations years before disease onset; whether this occurs in B lymphocytes before lymphoma remains uncertain. We sequenced multiple stages of the B lineage in elderly individuals and patients with lymphoplasmacytic lymphoma, a singular disease for studying lymphomagenesis because of the high prevalence of mutated
Indexed as
LymphomaLymphoma, B-CellWaldenstrom MacroglobulinemiaAgedAnimalsHumansMiceMutationMyeloid Differentiation Factor 88Myd88 protein, mouseMyeloid Differentiation Factor 88
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.